Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00258297 · ClinicalTrials.gov registry record · Phase 2
Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery
A Phase 2 study, sponsored by University of Rochester.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00258297 is a Phase 2 study that was terminated before completion, run by University of Rochester. The registered enrollment target is 30 participants.
The verdict
NCT00258297, a Phase 2 study, was terminated before completion, sponsored by University of Rochester.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gefitinib before surgery may shrink the tumor so that it can be removed. PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with stage I, stage II, or stage III esophageal cancer that can be removed by surgery.
Interventions
- PROCEDURE conventional surgery
- DRUG gefitinib
- PROCEDURE neoadjuvant therapy
- PROCEDURE enzyme inhibitor therapy
- PROCEDURE protein tyrosine kinase inhibitor therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-04 |
| Est. Completion | 2006-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00258297
The ClinicalTrials.gov registry entry for NCT00258297 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which conventional surgery is the first listed.
NCT00258297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00258297 about?
NCT00258297 is a clinical study titled "Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery". RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gefitinib before surgery may shrink the tumor so that it can be removed. PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with stage I, stage ...
What is the current status of trial NCT00258297?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2004-04. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00258297?
The interventions under investigation include: conventional surgery (PROCEDURE), gefitinib (DRUG), neoadjuvant therapy (PROCEDURE), enzyme inhibitor therapy (PROCEDURE), protein tyrosine kinase inhibitor therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00258297?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.